Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Catalyst Pharmaceuticals Inc shares valued at $4,736,000 were sold by INGENITO GARY on May 13 ’25. At $23.68 per share, INGENITO GARY sold 200,000 shares. The insider’s holdings dropped to 68,873 shares worth approximately $1.66 million following the completion of this transaction.
Also, INGENITO GARY sold 44,000 shares, netting a total of over 1,039,720 in proceeds. Following the sale of shares at $23.63 each, the insider now holds 68,873 shares.
Before that, INGENITO GARY had added 44,000 shares to its account. In a trade valued at $1,039,720, the Officer bought Catalyst Pharmaceuticals Inc shares for $23.63 each.
As published in their initiating research note from Robert W. Baird on February 04, 2025, Catalyst Pharmaceuticals Inc [CPRX] has been an Outperform and the price target has been revised to $28. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid November. As of March 14, 2024, Citigroup has initiated its “Buy” rating for CPRX. Earlier on March 07, 2024, BofA Securities initiated its rating. Their recommendation was “a Buy” for CPRX stock.
Analyzing CPRX Stock Performance
During the last five days, there has been a surge of approximately 1.39%. Over the course of the year, Catalyst Pharmaceuticals Inc shares have jumped approximately 15.52%. Shares of the company reached a 52-week high of $26.16 on 03/24/25 and a 52-week low of $19.15 on 01/08/25.
Support And Resistance Levels for Catalyst Pharmaceuticals Inc (CPRX)
According to the 24-hour chart, there is a support level at 23.86, which, if violated, would cause prices to drop to 23.62. In the upper region, resistance lies at 24.31. The next price resistance is at 24.52. RSI (Relative Strength Index) is 53.55 on the 14-day chart, showing neutral technical sentiment.
